Articles related to ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

Clinical trials demonstrate bupropion effectiveness at 150-450mg daily for ADHD symptom reduction, with extended-release formulations improving medication adherence through once-daily dosing.

Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

Methylphenidate significantly improved participants’ driving performance by reducing lane weaving and speed variation.

Analysis of more than 30,000 adult ADHD patients reveals significant increases in risk across 13 medical conditions, suggesting the need for comprehensive care protocols beyond standard ADHD management.

Analysis of more than 16.6 million pregnancies shows no significant increase in adverse outcomes for women maintaining methylphenidate or atomoxetine treatment during pregnancy.

The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.